title: Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer.
abstract: OBJECTIVE
  In this study, we evaluated the efficacy and tolerability of biweekly irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and folinic acid (FA) regimen (IFL) in patients with advanced stage colorectal cancer.
  
  
  METHODS
  A total of 28 patients were examined. The median age was 51 years (range, 30-74 years). One treatment cycle consisted of CPT-11 180 mg/m(2) on days 1 and 15; 5-FU 425 mg/m(2) on days 1, 2, 15 and 16; and FA 20 mg/m(2) on days 1, 2, 15 and 16, every 4 weeks. A total of 119 cycles (median, 4.0 cycles) were administered. Of the 28 patients, 18 received the chemotherapy as first line treatment, seven received it as second line and three received it as third line.
  
  
  RESULTS
  An overall objective response rate of 21.5% was achieved in the patient group. However, the overall response rate for the 18 patients receiving first line treatment was 27.7%. The median response duration was 10.5 months (range, 3-19 months). An additional 28.6% of the patients had stable disease for a median duration of 6.5 months (range, 3-8 months). Median time to disease progression was 4.5 months (range, 1-22+ months) and median overall survival time was 11+ months (95% confidence interval, 9-15 months). Toxicities were mild and manageable.
  
  
  CONCLUSIONS
  We conclude that biweekly IFL is a practical and tolerable treatment option with a disease control rate of 50.1% in patients with advanced stage colorectal cancer.
authors.affiliation: Department of Medical Oncology, Institute of Oncology, Hacettepe University, Ankara, Turkey. syalcin@hacettepe.edu.tr
authors.forename: Suayib
authors.initials: S
authors.lastname: Yalcin
authors.forename: Berna
authors.initials: B
authors.lastname: Oksuzoglu
authors.forename: Gülten
authors.initials: G
authors.lastname: Tekuzman
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Engin
authors.forename: Ismail
authors.initials: I
authors.lastname: Celik
authors.forename: Alev
authors.initials: A
authors.lastname: Turker
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Barista
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Gullu
authors.forename: Nilufer
authors.initials: N
authors.lastname: Guler
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Ozisik
authors.forename: Ayse
authors.initials: A
authors.lastname: Kars
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009367:Neoplasm Staging; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis
chemical_list: D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin